

CELGENE CORP /DE/  
Form 8-K  
December 10, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 9, 2007**

**CELGENE CORPORATION**  
(Exact name of registrant as specified in its charter)

**Delaware**                                      **0-16132**                                      **22-2711928**  
(State or other Jurisdiction of                      (Commission File Number)                      (IRS Employer Identification No.)  
Incorporation)

**86 Morris Avenue, Summit, New Jersey**                                      **07901**  
(Address of Principal Executive Offices)                                      (Zip Code)  
Registrant's telephone number, including area code: **(908) 673-9000**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 8.01 OTHER EVENTS**

On December 9, 2007, Celgene International Sarl announced that results from the Southwest Oncology Group, or SWOG, Phase III randomized, controlled trial evaluating REVLIMID® (lenalidomide) and the steroid dexamethasone were presented for the first time at the 49<sup>th</sup> annual American Society of Hematology, or ASH, meeting. The SWOG (S0232) study (Abstract #77) evaluated the combination therapy of REVLIMID® and dexamethasone in patients with newly diagnosed multiple myeloma and found that patients given the treatment regimen had superior response rates and progression-free survival compared to those who received dexamethasone alone.

Attached hereto and incorporated herein by reference as Exhibit 99.1 is the Press Release announcing such information.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibit 99.1 Press Release dated December 9, 2007

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CELGENE CORPORATION**

Date: December 10, 2007

By: /s/ David W. Gryska  
Name: David W. Gryska  
Title: Sr. Vice President and  
Chief Financial Officer